US20090270354A1 - Method of removing ticks from the skin and reducing the risk of bites - Google Patents

Method of removing ticks from the skin and reducing the risk of bites Download PDF

Info

Publication number
US20090270354A1
US20090270354A1 US12/498,971 US49897109A US2009270354A1 US 20090270354 A1 US20090270354 A1 US 20090270354A1 US 49897109 A US49897109 A US 49897109A US 2009270354 A1 US2009270354 A1 US 2009270354A1
Authority
US
United States
Prior art keywords
tick
skin
ticks
salicylic acid
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/498,971
Inventor
Carl P. Schaffner
William K. Griesinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Karykion Corp
Original Assignee
Karykion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karykion Corp filed Critical Karykion Corp
Priority to US12/498,971 priority Critical patent/US20090270354A1/en
Assigned to KARYKION INC. reassignment KARYKION INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GRIESINGER, WILLIAM K., SCHAFFNER, CARL P.
Publication of US20090270354A1 publication Critical patent/US20090270354A1/en
Priority to US13/177,811 priority patent/US8323672B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/42Phosphorus; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/14Ectoparasiticides, e.g. scabicides

Definitions

  • This invention relates to compositions, articles containing compositions, and methods of use of the compositions, for rapid and efficacious removal of ticks (Arthropods) attached to a mammal.
  • Ticks have life cycles starting with eggs produced by adult females. These hatch and progress to larvae, nymphs, and adults. With Lyme disease, the bite of the nymph offers the greatest risks to humans and animals and that of the adult less so.
  • the disease causing pathogen of Lyme disease is found in the gut of the blacklegged ticks where it remains inactive until warm blood enters the gut and enables it to grow and then move to the mouth of the tick. This process takes anywhere from 24 to 36 hours. Other tick-borne disease pathogens have even shorter growth periods.
  • the soft-shelled tick, Ornithodoros hermsi that causes Relapsing Fever requires only one hour or less to be available for infection at the bite site.
  • U.S. Pat. No. 6,808,717 discloses an aerosol coolant spray for killing and removing ticks comprising a coolant spray and essential oil.
  • aerosol canisters are undesirable due to the release of volatile organic compounds (VOCs) into the atmosphere that may cause pollution and depletion of the Earth's ozone layer.
  • VOCs volatile organic compounds
  • Other alternatives include using specially formulated shampoos that are safer for human and animal use such as those disclosed in Holzer, U.S. Pat. No. 6,683,065 and Bowman, U.S. Pat. No. 4,668,434. However, these methods may not be as effective at removing ticks due to the dilution of the effective chemicals.
  • an object of the invention to provide a new and improved composition and method for removing ticks from the skin of subjects such as humans and other animals and reducing the risk of tick bites.
  • Another object of the invention is to provide a composition and method of the above character which overcome the limitations and disadvantages of methods herefore employed in the removal of ticks.
  • compositions containing salicylic acid and an astringent are applied in amounts sufficient to render ineffective cementitious substances secreted by ticks to attach themselves to the skin and to constrict blood vessels near the skin and thereby keep blood away from the skin where ticks might feed upon it.
  • the composition is applied to the skin before a tick has attached itself to a subject to prevent ticks from attaching themselves to and biting the subject.
  • Tick insects are arthropods related to spiders, mites and fleas. There are a variety of ticks found throughout the world and they are dependent on animal and human hosts for survival. They are also excellent hosts in turn to many microbial pathogens including bacteria and viruses that are responsible for many diseases of humans and animals.
  • Lyme disease In the United States Lyme disease now account for more than 95 percent of all reported tick vector borne illnesses. In endemic areas 3 percent or more of the population experience the disease. Between 1982 and 2001 there has been a 25 fold increase in the incidence of Lyme disease in humans and the rate of disease progression and geographical area are increasing.
  • Lyme disease is caused by the bacterium Borrelia burgdorferi that is carried and supported by the black-legged tick, Ixodes scapularis , in Eastern and upper Midwestern United States. On the West Coast of the United States the blacklegged tick, Ixodes pacificus is involved in the cause of Lyme disease. In Europe and Asia the blacklegged ticks that serve as host carriers for Borrelia burgdorferi and cause Lyme disease are Ixodes ricinus and Ixodes persulcatus , respectively. Lyme disease is a multisystem infection caused generally by the bacterium, Borrelia burgdorferi , a spirochete that can infect both humans and different animals.
  • Lyme disease has a well-established infection pathway involving compatible host reservoirs such as mice and deer. As an essential vector blacklegged ticks transport the infectious bacterium from mice to humans.
  • Rocky Mountain Spotted Fever caused by Rickettsia rickittsi is hosted and transmitted by the tick, Dermacentor variabilis , found in the East and South of the United States while in the West the tick, Dermacentor Andersen , is involved in infection and transmission.
  • a more recent disease, Babesiosis, caused by Babesia microti is hosted by the blacklegged tick, Ixodes scapularis and found in the Northeast while on the West coast the tick, Ixodes pacificus , transmits the bacterium, Babesia equi .
  • the disease can be cotransmitted with Lyme disease and resembles malaria since the microbe invades red blood cells.
  • HME monocytic ehrlichiosis
  • Ixodes scapularis Ixodes pacifica and Dermacentor variabilis . This disease is found throughout the United States. The ticks can also cotransmit Lyme disease. Ehlichiosis is a serious disease since it is associated with some mortality.
  • tick-borne pathogens The following diseases due to tick-borne pathogens are relatively rarer.
  • Relapsing Fever which is found principally in the western United States is caused by Borrelia hermsii .
  • the disease is transmitted by the soft belly tick Ornithodoros hermsii .
  • Colorado Tick Fever (Mountain) is also found in the West and is caused by Colt virus that is hosted by the tick, Dermacentor Andersen .
  • Tularemia 35 (Deer Fly Fever or Rabbit Fever) is caused by the microbe, Francisella tularensis.
  • Tick Paralysis The disease, Tick Paralysis, is caused by a tick-produced toxin and not a microbe. In the West, Dermacentor Andersen is the tick involved whereas in the Eastern United States the tick, Dermacentor variabilis is involved.
  • ticks and tick-borne diseases are found throughout the world including Europe, Africa, Asia, and South America.
  • Ixodes scapularis and Ixodes pacificus serve as vectors for the Lyme disease pathogen, Borrelia burgdorferi ,in the United States
  • Ixodes ricinus serves as a tick vector in Europe and Ixodes persulcatus in Asia.
  • ticks of concern in this invention attach to the skin or tissues of mammals, such as humans, either directly through their body parts or initially by the secretion of cement substances that allow them to attach to the host followed by penetration of their mouth parts.
  • the invention provides a method of quickly extricating an embedded tick from the skin thereby preventing or reducing the risk of diseases associated with ticks such as, Lyme disease, Rocky Mountain Spotted Fever and Ehrlichiosis.
  • Salicylic acid or one of its analogs by virtue of their keratolytic action are employed in the invention to digest and remove dead flaky skin parts and tissues and tick-related cements that have held ticks to the skin of the host.
  • lotions and ointments are used as scrubs to remove dead skin parts from the surface areas of the body to improve the appearance, beauty and health of the individual.
  • An exfoliant e.g., salicylic acid or glycolic acid
  • Compositions described herein for the removal of ticks from epidermal tissue may comprise at least one exfoliant in an amount between about 1% and about 35% (glycolic acid, for example), typically in an amount between about 1% and about 25%.
  • compositions of this invention comprise an effective amount of salicylic acid or one of its analogs in solutions, lotions, ointments, and soaps to remove embedded ticks from the skin or tissues of human or animal hosts.
  • An effective concentration of salicylic acid or one of its analogs is typically one to five percent in solutions, lotions, ointments, and soaps and is dependent on the solubility of salicylic acid or one of its analogs, higher amounts are also contemplated (e.g., 150% salicylic acid or an analog thereof).
  • the compositions of the invention whether solutions, lotions, ointments, or soaps are used topically on the skin or tissues to remove embedded ticks from human or animal hosts. Liquid formulations to effect topical delivery of water soluble therapeutic agents are well known in the art, as described in Deckner, et al., U.S. Pat. No. 5,756,118, incorporated herein by reference.
  • compositions of the invention can also comprise alcohols such as ethyl alcohol, propyl alcohol, or isopropyl alcohol and alkyl glycols such as ethylene glycol or propylene glycol.
  • alcohols such as ethyl alcohol, propyl alcohol, or isopropyl alcohol
  • alkyl glycols such as ethylene glycol or propylene glycol.
  • the additional agents are useful to effect the solution of salicylic acid or one of its analogs otherwise insoluble and at concentrations that would be ineffective to remove embedded ticks from the skin or tissues of the human or animal host.
  • a composition of the invention can comprise an astringent used to constrict blood vessels.
  • the astringent may be, for example, Witch Hazel or aluminum salts including, but not limited to, aluminum sulfate, aluminum phosphate and aluminum acetate.
  • the composition comprises Witch Hazel.
  • exfoliant agents in combination with salicylic acid can be used in the compositions of the invention.
  • glycolic acid can be included along with salicylic acid in the compositions at a concentration/amount similar to that used in other skin compositions known in the art.
  • a composition of the invention comprises an aqueous composition of salicylic acid or an analog thereof having between about 0% to about 95% alcohol w/v.
  • Exemplary compositions of the invention comprise between about 2% to about 25% alcohol w/v.
  • Further example compositions of the invention comprise between about 5% to about 20% alcohol w/v or between about 7% to about 17% alcohol, e.g., about 8% w/v.
  • the compositions of the invention comprise between about 9% to about 16% alcohol w/v, e.g., ethanol and/or isopropanol in water.
  • formulations for topical administration of salicylic acid will typically comprise the agent in an amount between about 0.5% to about 10% w/v.
  • exemplary compositions described herein comprise salicylic acid in an amount between about 1 % to about 5% w/v.
  • Compositions typically will comprise salicylic acid for topical administration in an amount between about 1.5% to about 3.5% w/v, e.g., between about 2% to about 3% w/v or between about 1.5% to about 2.5% w/v, for example.
  • compositions of the invention can also comprise an effective amount of at least one astringent.
  • Typical astringents as components of formulations described herein include, for example, but are not limited to, Witch Hazel, aluminum sulphate, aluminum phosphate, aluminum acetate and the like, including zinc oxide, and iron oxide.
  • Distilled Witch Hazel is commonly sold in drug stores and pharmacies such as Witch Hazel Mixture 86%, Ethyl Alcohol (CAS #64175) 14%. This common composition is commercially available, for example, from Cumberland Swan One Swan Drive, Smyrna, TN 37167.
  • compositions of the invention can also comprise an effective amount of at least one anti-infective agent.
  • agents as components of compositions described herein include, but are not limited to, benzalkonium chloride, menthol, neomycin, bacitracin and polymyxin.
  • Anti-infective agents for example, make up from about 0.1% to about 1% w/v of the compositions described herein.
  • compositions comprising Salicylic acid useful in the methods of the invention are available from Neutrogena, sold under the name NEUTROGENA BLACKHEAD ELIMINATING Daily Scrub Ointment, which contains 2% Salicylic acid, water, cetyl alcohol, PPG15 stearyl ether, polyethylene, Methyl guceth20, steareth21, steareth2, polysorbate60, Glyceryl oleate, coco glucoside, linoleamidopropyl PGdimonium chloride phosphate, Neopentyl glycol dicaprylate/dicaprate, menthol, disodium EDTA, Xanthan gum, potassium cetyl phosphate, agar, mica, titanium dioxide, iron oxide, red 30 lake, and fragrance; and Clinque sold as Clinique Scruffing Lotion 3.5, which contains Witch Hazel, denatured alcohol, water (purified), salicylic acid, butylene glycol, benzalkonium chloride
  • composition(s) of the disclosure can be administered to any host, including a human or nonhuman animal, in an amount effective to inhibit tick biting and/or to cause removal of a tick from a subject.
  • the compositions are useful as anti-tick agents and may include antiviral agents, and/or antibacterial agents.
  • compositions of the disclosure can be formulated for topical administration (e.g., as a lotion, cream, spray, gel, or ointment).
  • topical administration e.g., as a lotion, cream, spray, gel, or ointment
  • formulations in the market place include topical lotions, creams, soaps, wipes, and the like. It may be formulated into liposomes to reduce toxicity or increase bioavailability. Aerosol delivery for transdermal applications may be used. Other methods of administration will be known to those skilled in the art.
  • Preparations will typically include sterile aqueous or non-aqueous solutions, suspensions, and emulsions.
  • non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils (e.g., olive oil), and organic esters such as ethyl oleate.
  • aqueous carriers include water, saline, and buffered media, alcoholic/aqueous solutions, and emulsions or suspensions.
  • Preservatives and other additives such as, other antimicrobial, antioxidants, chelating agents, inert gases and the like also can be included.
  • the disclosure provides a method for inhabiting a tick infection, or a tick-related bacterial or viral associated disease or disorder by contacting or administering a therapeutically effective amount of a composition of the disclosure to a subject who has, or is at risk of having a tick bite, infection or the like.
  • inhibiting means preventing or ameliorating a sign or symptoms of a tick infection or bite.
  • terapéuticaally effective amount means an amount of compositions sufficient to remove a tick from a subject's body surface, reduce the risk of a tick bite, and/or reduce the risk of infection by a tick-borne microbe.
  • a therapeutically effective amount can be measured as the amount sufficient to cause a tick to release from a subject or prevent a tick from biting a subject.
  • a suitable therapy regime can combine administration of a composition(s) of the disclosure with one or more additional agents, including antiviral and antibacterial agents.
  • the compositions, other therapeutic agents, and/or antibiotic(s) can be administered, simultaneously, but may also be administered sequentially.
  • Suitable antibiotics include aminoglycosides (e.g., gentamicin), betalactams (e.g., penicillins and cephalosporins), quinolones (e.g., ciprofloxacin), and novobiocin.
  • the antibiotic is administered in a bactericidal amount.
  • the peptide provides for a method of increasing antibiotic activity by permeabilizing the bacterial outer membrane and combinations involving peptide and a subinhibitory amount (an amount lower than the bactericidal amount) of antibiotic can be administered.
  • a “bactericidal amount” is an amount sufficient to achieve a bacteria killing blood concentration or bacterial killing local concentration in the subject receiving the treatment.
  • an “antibiotic,” as used herein is a chemical substance that, in dilute solutions, inhibits the growth of, or kills microorganisms. Also encompassed by this term are synthetic antibiotics (e.g., analogs) known in the art.
  • kits or article of manufacture comprising a composition of the invention and a writing associated the kit or article.
  • the article of manufacture or kit may be, for example, but not limited to a container, bottle or any other means for storing an aqueous solution.
  • the article may be any shape, such as cylindrical, spherical, cubic or conic and any size.
  • the article may be any material suitable for storing the herein described composition such as any plastics, metals or glass.
  • the writing associated with the article or kit indicates that the composition is useful for removal of ticks.
  • the writing may be for example, but not limited to, instructions for using the herein described composition to remove ticks from a person or animals skin.
  • the instructions may be attached directly to the article or packaged separately with the article.
  • An embedded wood tick ( Dermacentor variabilis ) in the skin of a human is treated topically with a cotton wipe containing a solution or lotion of 2 percent salicylic acid in aqueous alcohol containing benzalkonium chloride. The tick withdraws from the skin within 20 seconds.
  • An embedded wood tick Dermacentor variabilis in the skin within the hair of a dog is treated topically with a cotton wipe saturated with a lotion of 2 percent salicylic acid in aqueous alcohol containing benzalkonium chloride. The tick withdraws from the skin within 30 seconds.
  • An embedded deer tick ( Ixodes scapularis ) on the skin of a human is treated topically with a cotton wipe containing a lotion of 2 percent salicylic acid an benzalkonium chloride. The tick withdraws from the skin within 20 seconds.
  • An embedded deer tick ( Ixodes scapularis ) on the skin of a human is treated topically by applying an ointment containing 5 percent salicylic acid and benzalkonium chloride the tick withdraws from the skin after 30 seconds.
  • An embedded Lone Star tick ( Amblyomma americananum ) on the skin of a human is treated topically by applying an ointment containing 5 percent salicylic acid and benzalkonium chloride. The tick withdraws from the skin within 30 seconds.
  • An embedded Lone Star tick ( Amblyomma americananum ) on the skin within the hair of a dog is treated topically with an ointment containing 5 percent salicylic acid and benzalkonium chloride. The tick withdraws from the skin within 30 seconds.
  • An embedded deer tick ( Ixodes scapularis ) on the skin within the hair of a dog is treated topically with a cotton wipe saturated with a lotion containing 2 percent salicylic acid and menthol in aqueous alcohol. The tick withdraws from the skin within 30 seconds.
  • An embedded wood tick ( Dermacentor variabilis ) on the skin of a human is treated topically with a cotton wipe containing a lotion of 2 percent salicylic acid and neomycin, bacitracin, and polymyxin in aqueous alcohol. The tick withdraws from the skin within 30 seconds.

Abstract

Compositions and method of using the same for the removal of ticks embedded in the skin or tissue of a human or animal host and for preventing ticks from attaching themselves to and biting humans or other animals.

Description

    RELATED APPLICATIONS
  • Continuation of Ser. No. 11/512,555, filed Aug. 29, 2006, the priority of which is claimed.
  • BACKGROUND OF THE INVENTION
  • 1. Field of Invention
  • This invention relates to compositions, articles containing compositions, and methods of use of the compositions, for rapid and efficacious removal of ticks (Arthropods) attached to a mammal.
  • 2. Related Art
  • Ticks have life cycles starting with eggs produced by adult females. These hatch and progress to larvae, nymphs, and adults. With Lyme disease, the bite of the nymph offers the greatest risks to humans and animals and that of the adult less so. The disease causing pathogen of Lyme disease is found in the gut of the blacklegged ticks where it remains inactive until warm blood enters the gut and enables it to grow and then move to the mouth of the tick. This process takes anywhere from 24 to 36 hours. Other tick-borne disease pathogens have even shorter growth periods. The soft-shelled tick, Ornithodoros hermsi that causes Relapsing Fever requires only one hour or less to be available for infection at the bite site. Hauser, Susan Carol, 2001, in “Outwitting Ticks”, The Lyons Press, Connecticut, presents an extensive survey of the role of ticks in human and animal diseases, their description, location, prevention and treatment. The conclusion of this author and all health authorities is that embedded ticks of all types should be removed as quickly as possible. In the case of Lyme disease the tick should be removed before 24 hours after the time of attachment. This process is not always so simple.
  • Various household methods currently attempt to remove ticks ranging from applying heat or various chemical compositions. However, these household remedies may not be safe due to the potential danger of burning skin when applying heat or because many of the chemicals can be unhealthy and adversely react with human skin causing irritations or rashes.
  • Others have attempted to create less dangerous methods for removing ticks. For example Bale, U.S. Pat. No. 6,808,717 discloses an aerosol coolant spray for killing and removing ticks comprising a coolant spray and essential oil. However, using aerosol canisters are undesirable due to the release of volatile organic compounds (VOCs) into the atmosphere that may cause pollution and depletion of the Earth's ozone layer. Other alternatives include using specially formulated shampoos that are safer for human and animal use such as those disclosed in Holzer, U.S. Pat. No. 6,683,065 and Bowman, U.S. Pat. No. 4,668,434. However, these methods may not be as effective at removing ticks due to the dilution of the effective chemicals.
  • OBJECTS AND SUMMARY OF THE INVENTION
  • It is, in general, an object of the invention to provide a new and improved composition and method for removing ticks from the skin of subjects such as humans and other animals and reducing the risk of tick bites.
  • Another object of the invention is to provide a composition and method of the above character which overcome the limitations and disadvantages of methods herefore employed in the removal of ticks.
  • These and other objects are achieved in accordance with the invention by applying a composition containing salicylic acid and an astringent to a tick and/or to a subject near the tick in an amount sufficient to disengage the tick from the subject. The salicylic acid and the astringent are applied in amounts sufficient to render ineffective cementitious substances secreted by ticks to attach themselves to the skin and to constrict blood vessels near the skin and thereby keep blood away from the skin where ticks might feed upon it. In some embodiments, the composition is applied to the skin before a tick has attached itself to a subject to prevent ticks from attaching themselves to and biting the subject.
  • DETAILED DESCRIPTION
  • Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this invention belongs. All publications and patents referred to herein are incorporated by reference.
  • Tick insects are arthropods related to spiders, mites and fleas. There are a variety of ticks found throughout the world and they are dependent on animal and human hosts for survival. They are also excellent hosts in turn to many microbial pathogens including bacteria and viruses that are responsible for many diseases of humans and animals.
  • In the United States Lyme disease now account for more than 95 percent of all reported tick vector borne illnesses. In endemic areas 3 percent or more of the population experience the disease. Between 1982 and 2001 there has been a 25 fold increase in the incidence of Lyme disease in humans and the rate of disease progression and geographical area are increasing.
  • Lyme disease is caused by the bacterium Borrelia burgdorferi that is carried and supported by the black-legged tick, Ixodes scapularis, in Eastern and upper Midwestern United States. On the West Coast of the United States the blacklegged tick, Ixodes pacificus is involved in the cause of Lyme disease. In Europe and Asia the blacklegged ticks that serve as host carriers for Borrelia burgdorferi and cause Lyme disease are Ixodes ricinus and Ixodes persulcatus, respectively. Lyme disease is a multisystem infection caused generally by the bacterium, Borrelia burgdorferi, a spirochete that can infect both humans and different animals.
  • Another spirochete that causes the disease, syphilis, does not require a tick transmission host but infects human to human. Lyme disease has a well-established infection pathway involving compatible host reservoirs such as mice and deer. As an essential vector blacklegged ticks transport the infectious bacterium from mice to humans.
  • In the United States there are other tick-borne diseases of considerable importance to human health. Rocky Mountain Spotted Fever caused by Rickettsia rickittsi is hosted and transmitted by the tick, Dermacentor variabilis, found in the East and South of the United States while in the West the tick, Dermacentor Andersen, is involved in infection and transmission. A more recent disease, Babesiosis, caused by Babesia microti is hosted by the blacklegged tick, Ixodes scapularis and found in the Northeast while on the West coast the tick, Ixodes pacificus, transmits the bacterium, Babesia equi. The disease can be cotransmitted with Lyme disease and resembles malaria since the microbe invades red blood cells.
  • A more recently identified tick related disease called Erhlichiosis is caused by rickettsial bacteria. There are two distinct forms of the disease. One form known as monocytic ehrlichiosis (HME) is caused by the rickettsial bacterium, Ehrlichia chaffeensis and is hosted and transmitted by the ticks, Dermacentor variabilis and Amblyomma americanum. This form of the disease is found in the South-central and South Atlantic parts of the United States. The second disease form is granulocytic ehrlichiosis (HGE) and is caused by Ehrlichia equi. It is hosted and transmitted by the ticks, Ixodes scapularis, Ixodes pacifica and Dermacentor variabilis. This disease is found throughout the United States. The ticks can also cotransmit Lyme disease. Ehlichiosis is a serious disease since it is associated with some mortality.
  • The following diseases due to tick-borne pathogens are relatively rarer. Relapsing Fever which is found principally in the western United States is caused by Borrelia hermsii. The disease is transmitted by the soft belly tick Ornithodoros hermsii. Colorado Tick Fever (Mountain) is also found in the West and is caused by Colt virus that is hosted by the tick, Dermacentor Andersen. Tularemia 35 (Deer Fly Fever or Rabbit Fever) is caused by the microbe, Francisella tularensis.
  • The disease, Tick Paralysis, is caused by a tick-produced toxin and not a microbe. In the West, Dermacentor Andersen is the tick involved whereas in the Eastern United States the tick, Dermacentor variabilis is involved.
  • While the United States has a number of different ticks that host various disease related microbial pathogens for humans and animals, similar ticks and tick-borne diseases are found throughout the world including Europe, Africa, Asia, and South America. As an example, while Ixodes scapularis and Ixodes pacificus serve as vectors for the Lyme disease pathogen, Borrelia burgdorferi,in the United States, Ixodes ricinus serves as a tick vector in Europe and Ixodes persulcatus in Asia.
  • All ticks of concern in this invention attach to the skin or tissues of mammals, such as humans, either directly through their body parts or initially by the secretion of cement substances that allow them to attach to the host followed by penetration of their mouth parts. The invention provides a method of quickly extricating an embedded tick from the skin thereby preventing or reducing the risk of diseases associated with ticks such as, Lyme disease, Rocky Mountain Spotted Fever and Ehrlichiosis.
  • Salicylic acid or one of its analogs by virtue of their keratolytic action are employed in the invention to digest and remove dead flaky skin parts and tissues and tick-related cements that have held ticks to the skin of the host. In the cosmetic trade, lotions and ointments are used as scrubs to remove dead skin parts from the surface areas of the body to improve the appearance, beauty and health of the individual. The unexpected finding that a scrubbing lotion could effectively and quickly remove an embedded tick from the skin is the basis of this invention. An exfoliant, e.g., salicylic acid or glycolic acid, is an important element of the compositions described herein. Compositions described herein for the removal of ticks from epidermal tissue may comprise at least one exfoliant in an amount between about 1% and about 35% (glycolic acid, for example), typically in an amount between about 1% and about 25%.
  • Compositions of this invention comprise an effective amount of salicylic acid or one of its analogs in solutions, lotions, ointments, and soaps to remove embedded ticks from the skin or tissues of human or animal hosts. An effective concentration of salicylic acid or one of its analogs is typically one to five percent in solutions, lotions, ointments, and soaps and is dependent on the solubility of salicylic acid or one of its analogs, higher amounts are also contemplated (e.g., 150% salicylic acid or an analog thereof). The compositions of the invention whether solutions, lotions, ointments, or soaps are used topically on the skin or tissues to remove embedded ticks from human or animal hosts. Liquid formulations to effect topical delivery of water soluble therapeutic agents are well known in the art, as described in Deckner, et al., U.S. Pat. No. 5,756,118, incorporated herein by reference.
  • In addition to salicylic acid or analogs thereof, the compositions of the invention can also comprise alcohols such as ethyl alcohol, propyl alcohol, or isopropyl alcohol and alkyl glycols such as ethylene glycol or propylene glycol. In some aspects, the additional agents are useful to effect the solution of salicylic acid or one of its analogs otherwise insoluble and at concentrations that would be ineffective to remove embedded ticks from the skin or tissues of the human or animal host.
  • In yet a further aspect, a composition of the invention can comprise an astringent used to constrict blood vessels. The astringent may be, for example, Witch Hazel or aluminum salts including, but not limited to, aluminum sulfate, aluminum phosphate and aluminum acetate. In an exemplary embodiment of the invention, the composition comprises Witch Hazel.
  • Other exfoliant agents in combination with salicylic acid can be used in the compositions of the invention. For example, glycolic acid can be included along with salicylic acid in the compositions at a concentration/amount similar to that used in other skin compositions known in the art.
  • In one embodiment, a composition of the invention comprises an aqueous composition of salicylic acid or an analog thereof having between about 0% to about 95% alcohol w/v. Exemplary compositions of the invention comprise between about 2% to about 25% alcohol w/v. Further example compositions of the invention comprise between about 5% to about 20% alcohol w/v or between about 7% to about 17% alcohol, e.g., about 8% w/v. In a specific embodiment, the compositions of the invention comprise between about 9% to about 16% alcohol w/v, e.g., ethanol and/or isopropanol in water.
  • Moreover, formulations for topical administration of salicylic acid will typically comprise the agent in an amount between about 0.5% to about 10% w/v. Exemplary compositions described herein comprise salicylic acid in an amount between about 1 % to about 5% w/v. Compositions typically will comprise salicylic acid for topical administration in an amount between about 1.5% to about 3.5% w/v, e.g., between about 2% to about 3% w/v or between about 1.5% to about 2.5% w/v, for example.
  • Compositions of the invention can also comprise an effective amount of at least one astringent. Typical astringents as components of formulations described herein include, for example, but are not limited to, Witch Hazel, aluminum sulphate, aluminum phosphate, aluminum acetate and the like, including zinc oxide, and iron oxide. Distilled Witch Hazel is commonly sold in drug stores and pharmacies such as Witch Hazel Mixture 86%, Ethyl Alcohol (CAS #64175) 14%. This common composition is commercially available, for example, from Cumberland Swan One Swan Drive, Smyrna, TN 37167.
  • Compositions of the invention can also comprise an effective amount of at least one anti-infective agent. Such agents as components of compositions described herein include, but are not limited to, benzalkonium chloride, menthol, neomycin, bacitracin and polymyxin. Anti-infective agents, for example, make up from about 0.1% to about 1% w/v of the compositions described herein.
  • Commercially available compositions comprising Salicylic acid useful in the methods of the invention are available from Neutrogena, sold under the name NEUTROGENA BLACKHEAD ELIMINATING Daily Scrub Ointment, which contains 2% Salicylic acid, water, cetyl alcohol, PPG15 stearyl ether, polyethylene, Methyl guceth20, steareth21, steareth2, polysorbate60, Glyceryl oleate, coco glucoside, linoleamidopropyl PGdimonium chloride phosphate, Neopentyl glycol dicaprylate/dicaprate, menthol, disodium EDTA, Xanthan gum, potassium cetyl phosphate, agar, mica, titanium dioxide, iron oxide, red 30 lake, and fragrance; and Clinque sold as Clinique Scruffing Lotion 3.5, which contains Witch Hazel, denatured alcohol, water (purified), salicylic acid, butylene glycol, benzalkonium chloride, disodium EDTA copper, disodium EDTA, d & c green No. 5, and fd & c blue No. 1. Clinique also sells Clinique Body Scrub Ointment containing salicylic acid.
  • The composition(s) of the disclosure can be administered to any host, including a human or nonhuman animal, in an amount effective to inhibit tick biting and/or to cause removal of a tick from a subject. Thus, the compositions are useful as anti-tick agents and may include antiviral agents, and/or antibacterial agents.
  • Any of a variety of art known methods can be used to administer the compositions to a subject. For example, the compositions of the disclosure can be formulated for topical administration (e.g., as a lotion, cream, spray, gel, or ointment). Examples of formulations in the market place include topical lotions, creams, soaps, wipes, and the like. It may be formulated into liposomes to reduce toxicity or increase bioavailability. Aerosol delivery for transdermal applications may be used. Other methods of administration will be known to those skilled in the art.
  • Preparations will typically include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils (e.g., olive oil), and organic esters such as ethyl oleate. Examples of aqueous carriers include water, saline, and buffered media, alcoholic/aqueous solutions, and emulsions or suspensions. Preservatives and other additives such as, other antimicrobial, antioxidants, chelating agents, inert gases and the like also can be included.
  • The disclosure provides a method for inhabiting a tick infection, or a tick-related bacterial or viral associated disease or disorder by contacting or administering a therapeutically effective amount of a composition of the disclosure to a subject who has, or is at risk of having a tick bite, infection or the like. The term “inhibiting” means preventing or ameliorating a sign or symptoms of a tick infection or bite.
  • The term “therapeutically effective amount” as used herein means an amount of compositions sufficient to remove a tick from a subject's body surface, reduce the risk of a tick bite, and/or reduce the risk of infection by a tick-borne microbe. For example, a therapeutically effective amount can be measured as the amount sufficient to cause a tick to release from a subject or prevent a tick from biting a subject.
  • If desired, a suitable therapy regime can combine administration of a composition(s) of the disclosure with one or more additional agents, including antiviral and antibacterial agents. The compositions, other therapeutic agents, and/or antibiotic(s) can be administered, simultaneously, but may also be administered sequentially. Suitable antibiotics include aminoglycosides (e.g., gentamicin), betalactams (e.g., penicillins and cephalosporins), quinolones (e.g., ciprofloxacin), and novobiocin. Generally, the antibiotic is administered in a bactericidal amount. However, the peptide provides for a method of increasing antibiotic activity by permeabilizing the bacterial outer membrane and combinations involving peptide and a subinhibitory amount (an amount lower than the bactericidal amount) of antibiotic can be administered. A “bactericidal amount” is an amount sufficient to achieve a bacteria killing blood concentration or bacterial killing local concentration in the subject receiving the treatment. In accordance with its conventional definition, an “antibiotic,” as used herein, is a chemical substance that, in dilute solutions, inhibits the growth of, or kills microorganisms. Also encompassed by this term are synthetic antibiotics (e.g., analogs) known in the art.
  • The invention also provides kits or article of manufacture comprising a composition of the invention and a writing associated the kit or article. The article of manufacture or kit may be, for example, but not limited to a container, bottle or any other means for storing an aqueous solution. The article may be any shape, such as cylindrical, spherical, cubic or conic and any size. The article may be any material suitable for storing the herein described composition such as any plastics, metals or glass.
  • The writing associated with the article or kit indicates that the composition is useful for removal of ticks. The writing may be for example, but not limited to, instructions for using the herein described composition to remove ticks from a person or animals skin. The instructions may be attached directly to the article or packaged separately with the article.
  • All publications and patents referred to herein are incorporated by reference. Various modifications and variations of the described subject matter will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific embodiments, it should be understood that the invention as claimed should not be unduly limited to these embodiments. Indeed, various modifications for carrying out the invention are obvious to those skilled in the art and are intended to be within the scope of the following claims.
  • EXAMPLE I
  • An embedded wood tick (Dermacentor variabilis) in the skin of a human is treated topically with a cotton wipe containing a solution or lotion of 2 percent salicylic acid in aqueous alcohol containing benzalkonium chloride. The tick withdraws from the skin within 20 seconds.
  • EXAMPLE II
  • An embedded wood tick (Dermacentor variabilis) in the skin within the hair of a dog is treated topically with a cotton wipe saturated with a lotion of 2 percent salicylic acid in aqueous alcohol containing benzalkonium chloride. The tick withdraws from the skin within 30 seconds.
  • EXAMPLE III
  • An embedded deer tick (Ixodes scapularis) on the skin of a human is treated topically with a cotton wipe containing a lotion of 2 percent salicylic acid an benzalkonium chloride. The tick withdraws from the skin within 20 seconds.
  • EXAMPLE IV
  • An embedded deer tick (Ixodes scapularis) on the skin of a human is treated topically by applying an ointment containing 5 percent salicylic acid and benzalkonium chloride the tick withdraws from the skin after 30 seconds.
  • EXAMPLE V
  • An embedded Lone Star tick (Amblyomma americananum) on the skin of a human is treated topically by applying an ointment containing 5 percent salicylic acid and benzalkonium chloride. The tick withdraws from the skin within 30 seconds.
  • EXAMPLE VI
  • An embedded Lone Star tick (Amblyomma americananum) on the skin within the hair of a dog is treated topically with an ointment containing 5 percent salicylic acid and benzalkonium chloride. The tick withdraws from the skin within 30 seconds.
  • EXAMPLE VII
  • An embedded deer tick (Ixodes scapularis) on the skin within the hair of a dog is treated topically with a cotton wipe saturated with a lotion containing 2 percent salicylic acid and menthol in aqueous alcohol. The tick withdraws from the skin within 30 seconds.
  • EXAMPLE VIII
  • An embedded wood tick (Dermacentor variabilis) on the skin of a human is treated topically with a cotton wipe containing a lotion of 2 percent salicylic acid and neomycin, bacitracin, and polymyxin in aqueous alcohol. The tick withdraws from the skin within 30 seconds.
  • EXAMPLE IX
  • An embedded wood tick (dog tick, Dermacentor variabilis) on the skin of a human was treated topically with a cotton swab comprising a lotion of salicylic acid, Witch Hazel, and benzalkonium chloride. It took about 15 seconds for the tick to disengage from the skin.
  • EXAMPLE X
  • An embedded wood tick (dog tick, Dermacentor variabilis) on the skin within the hair of a dog was treated topically with a cotton swab comprising a lotion of salicylic acid, Witch Hazel, and benzalkonium chloride. It took about 15 seconds for the tick to disengage from the skin.
  • EXAMPLE XI
  • An embedded wood tick (dog tick, Dermacentor variabilis) on the skin within the hair of a cat was treated topically with a cotton swab comprising a lotion of salicylic acid, Witch Hazel, and benzalkonium chloride. It took about 15 seconds for the tick to disengage from the skin.
  • It is apparent from the foregoing that a new and improved composition and method for removing ticks embedded in the skin and preventing ticks from attaching themselves to and biting humans or other animals have been provided. While only certain presently preferred embodiments have been described in detail, as will be apparent to those familiar with the art, certain changes and modifications can be made without departing from the scope of the invention as defined by the following claims.

Claims (10)

1. A method of removing a tick from a subject, comprising the step of applying a composition containing salicylic acid and an astringent to the tick and/or to the subject near the tick in an amount sufficient to disengage the tick from the subject.
2. The method of claim 1, wherein the salicylic acid is present in an amount effective to exfoliate a cementitious substance attaching the tick to the subject.
3. The method of claim 1, wherein the astringent is present in an amount effective to constrict blood vessels near the tick and thereby keep blood away from the tick while the tick is being disengaged from the subject.
4. The method of claim 1, wherein the composition also contains an effective amount of at least one anti-infective agent.
5. A method of reducing the risk of tick bites in humans and other comprising the step of contacting the epidermal tissue of a human or other mammal with a composition containing salicylic acid in an amount sufficient to inhibit a tick from cementitiously attaching itself to the tissue to bite the human or other mammal.
6. A method of removing ticks from the skin and reducing the risk of tick bites in humans and other mammals, comprising the step of applying a composition containing salicylic acid and at least one astringent to the skin in amounts sufficient to render ineffective cementitious substances secreted by ticks to attach themselves to the skin and to constrict blood vessels near the skin and thereby keep blood away from the skin where ticks might feed upon it.
7. The method of claim 6 wherein the composition is applied to the skin near a tick that has already attached itself to the skin.
8. The method of claim 6 wherein the composition is applied to the skin before any ticks have attached themselves to the skin.
9. A method of removing ticks from the skin of humans and other mammals, comprising the step of applying an exfoliant to a tick and/or the skin near the tick in an amount effective to remove any cementitious substance secreted by the tick in attaching itself to the skin.
10. The method of claim 9 wherein the exfoliant is selected from the group consisting of salicylic acid, glycolic acid, and combinations thereof.
US12/498,971 2006-08-29 2009-07-07 Method of removing ticks from the skin and reducing the risk of bites Abandoned US20090270354A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/498,971 US20090270354A1 (en) 2006-08-29 2009-07-07 Method of removing ticks from the skin and reducing the risk of bites
US13/177,811 US8323672B2 (en) 2006-08-29 2011-07-07 Method of removing ticks from the skin and reducing the risk of bites

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/512,555 US7604814B2 (en) 2006-08-29 2006-08-29 Method of removing ticks from the epidermal tissue of humans and other mammals
US12/498,971 US20090270354A1 (en) 2006-08-29 2009-07-07 Method of removing ticks from the skin and reducing the risk of bites

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US11/512,555 Continuation US7604814B2 (en) 2006-08-29 2006-08-29 Method of removing ticks from the epidermal tissue of humans and other mammals

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/177,811 Continuation-In-Part US8323672B2 (en) 2006-08-29 2011-07-07 Method of removing ticks from the skin and reducing the risk of bites

Publications (1)

Publication Number Publication Date
US20090270354A1 true US20090270354A1 (en) 2009-10-29

Family

ID=39136584

Family Applications (2)

Application Number Title Priority Date Filing Date
US11/512,555 Expired - Fee Related US7604814B2 (en) 2006-08-29 2006-08-29 Method of removing ticks from the epidermal tissue of humans and other mammals
US12/498,971 Abandoned US20090270354A1 (en) 2006-08-29 2009-07-07 Method of removing ticks from the skin and reducing the risk of bites

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US11/512,555 Expired - Fee Related US7604814B2 (en) 2006-08-29 2006-08-29 Method of removing ticks from the epidermal tissue of humans and other mammals

Country Status (4)

Country Link
US (2) US7604814B2 (en)
EP (1) EP2061309B1 (en)
CA (1) CA2696959A1 (en)
WO (1) WO2008027470A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120090219A1 (en) * 2010-10-19 2012-04-19 Joseph Luongo Apparatus for killing and removing ticks

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8323672B2 (en) 2006-08-29 2012-12-04 Karykion Corporation Method of removing ticks from the skin and reducing the risk of bites
WO2011090747A2 (en) 2009-12-29 2011-07-28 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations System and method for providing assessment of risk of encounter with ticks
US9615565B2 (en) 2013-09-12 2017-04-11 Patricia L. Singleterry Device, method and system for killing and disposing of parasites

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4668434A (en) * 1985-12-31 1987-05-26 Zema Corporation Pet shampoo
US5756118A (en) * 1991-10-16 1998-05-26 Richardson-Vicks Inc. Enhanced skin penetration system for improved topical delivery of drugs
US6683065B1 (en) * 1999-08-19 2004-01-27 Host Pharmaceuticals Llc Method of treating body insect infestation
US20040157766A1 (en) * 2003-01-23 2004-08-12 Edko Trading And Representation Co. Ltd. Topical pharmaceutical and/or cosmetic dispense systems
US6808717B1 (en) * 2003-05-23 2004-10-26 Isidore Bale Aerosol coolant spray for killing and removing ticks
US20060008538A1 (en) * 2004-07-07 2006-01-12 Wu Jeffrey M Methods of treating the skin
US20060275218A1 (en) * 2003-08-04 2006-12-07 Foamix Ltd. Foamable vehicle and pharmaceutical compositions thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060153935A1 (en) * 2005-01-07 2006-07-13 Natalie Blahut Stabilizing salicylate compositions and method of preparation for oral and topical use

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4668434A (en) * 1985-12-31 1987-05-26 Zema Corporation Pet shampoo
US5756118A (en) * 1991-10-16 1998-05-26 Richardson-Vicks Inc. Enhanced skin penetration system for improved topical delivery of drugs
US6683065B1 (en) * 1999-08-19 2004-01-27 Host Pharmaceuticals Llc Method of treating body insect infestation
US20040157766A1 (en) * 2003-01-23 2004-08-12 Edko Trading And Representation Co. Ltd. Topical pharmaceutical and/or cosmetic dispense systems
US6808717B1 (en) * 2003-05-23 2004-10-26 Isidore Bale Aerosol coolant spray for killing and removing ticks
US20060275218A1 (en) * 2003-08-04 2006-12-07 Foamix Ltd. Foamable vehicle and pharmaceutical compositions thereof
US20060008538A1 (en) * 2004-07-07 2006-01-12 Wu Jeffrey M Methods of treating the skin

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120090219A1 (en) * 2010-10-19 2012-04-19 Joseph Luongo Apparatus for killing and removing ticks
US8844193B2 (en) * 2010-10-19 2014-09-30 Joseph Luongo Apparatus for killing and removing ticks

Also Published As

Publication number Publication date
CA2696959A1 (en) 2008-03-06
US20080057018A1 (en) 2008-03-06
EP2061309A4 (en) 2010-10-06
US7604814B2 (en) 2009-10-20
EP2061309A2 (en) 2009-05-27
WO2008027470A3 (en) 2008-12-11
EP2061309B1 (en) 2015-10-28
WO2008027470A2 (en) 2008-03-06

Similar Documents

Publication Publication Date Title
US10195239B2 (en) Extract of Trigonella foenum-graecum
US9814737B2 (en) Composition for skin sanitization and protection and method of its use
US5399349A (en) Treatment of acne
US8323672B2 (en) Method of removing ticks from the skin and reducing the risk of bites
BG64522B1 (en) Device for the treatment of viral infectiuous diseases
US9775872B2 (en) Topical pharmaceutical bases for preventing viral diseases
US20170157258A1 (en) Povidone-iodine topical composition
Özan et al. Effect of mouthrinse containing propolis on oral microorganisms and human gingival fibroblasts
Chhetri et al. Formulation and evaluation of antimicrobial herbal ointment
EP2061309B1 (en) Compositions and methods of use thereof for the removal of ticks from epidermal tissue
DE2709121C2 (en)
NO333349B1 (en) Delivery system for insertion into the outer ear canal comprising a volatile substance to treat or prevent middle ear inflammation.
Roqaiya et al. A review on medicinal aspect of alum in Unani medicine and scientific studies
JP2005060320A (en) Skin acaricide and external preparation for skin containing the same acaricide
JP2002501901A (en) Antiviral agent for plants
US20170020946A1 (en) Analgesic compositions and methods of use
JPS6333326A (en) Antibacterial composition
US20110301617A1 (en) System and Method for Immobilizing a Tick on a Host
JP2004189656A (en) Composition for resisting acne bacterium
US20160184220A1 (en) Method for the Prevention and Treatment of Acne
KR20100117261A (en) Composite of shampoo
US20030091650A1 (en) Ratite oil as a topical adjuvant and transdermal carrier
Cirillo Oil of Turpentine: Sheet Anchor of 19th-Century Therapeutics
EP4311545A1 (en) Compounds useful for the post-sting treatment from a cnidarian organism
Halstead Marine biotoxicology

Legal Events

Date Code Title Description
AS Assignment

Owner name: KARYKION INC., NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SCHAFFNER, CARL P.;GRIESINGER, WILLIAM K.;REEL/FRAME:022923/0838

Effective date: 20080430

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION